We are live on ! Find out more

BLLN

BillionToOne Inc

BLLN

Market cap $4.99B

105.76 USD

-0.68

0.64%

At close Updated Oct 1, 4:00 PM EDT

Pre-market

After hours

105.76

0.00

0%

1 day

-0.64%

5 days

-15.52%

1 month

14.56%

3 months

-13.55%

6 months

27.48%

Year to date

18.45%

1 year

-2.92%

5 years

-2.92%

10 years

-2.92%

About: BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Employees: 713

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 16.7%

Neutral 61.1%

Negative 22.2%

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently

The Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, aiming to curb excessive Medicare payments and save taxpayers an estimated $1 billion annually.

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently

The Motley Fool

BillionToOne SVP Sells 1,416 Shares

The transaction involved 1,416 shares at a weighted average price of $97.54 per share, totaling $138,116 on Sept. 9, 2026. The sale involved shares equal to 5% of the direct equity position held before the transaction.

BillionToOne SVP Sells 1,416 Shares

The Motley Fool

BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million

The transaction involved 30,331 shares executed at a weighted average price of $99.91 per share on September 14, 2026. The shares traded in this filing represented 100% of the insider's directly-held equity stake, and a portion belonging to his spouse.

BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million

BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference

MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference.

BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference

BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin

New add-on test from a single blood draw; BillionToOne also expands Northstar Select® panel to 102 genes MENLO PARK, Calif., Sept. 1, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar Origin™, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select® panel from 84 to 102 genes to cover genes that are included in recent and upcoming FDA approvals.

BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin

The Motley Fool

BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million

The transaction involved 10,000 shares at a weighted-average price of $100.00 per share, totaling $1.0 million on the August 25, 2026 transaction date. Following the disposal, the insider holds a direct position of 1,000 shares, which represents approximately 0.0022% of the company's total shares outstanding.

BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results MENLO PARK, Calif., Aug. 18, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population in The Green Journal.

Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

BillionToOne: A Softer Quarter After Heightened Expectations

BillionToOne experienced a sharp post-earnings sell-off despite maintaining full-year guidance and strong year-over-year revenue growth. Second quarter results showed slowing sequential growth, softer average selling prices, and significant margin compression versus Q1. The company trades at ~10x sales, a premium to May levels, with the growth story intact but near-term valuation less attractive.

BillionToOne: A Softer Quarter After Heightened Expectations

Investors Business Daily

Why BillionToOne Plummeted 36%, Leading A Medtech Sell-Off

Medical research stocks took a bath Thursday, helped by BillionToOne's second-quarter report, featuring a beat but no guidance raise.

Why BillionToOne Plummeted 36%, Leading A Medtech Sell-Off

Zacks Investment Research

BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Say

See News Rankings

Price charts implemented using Lightweight Charts™